Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers

Archives of General Psychiatry

Volumn 68, Issue 6, 2011, Pages 545-554

  O'Daly, Owen Gareth ^a   Joyce, Daniel ^a   Stephan, Klaas Enno ^b,c   Murray, Robin McGregor ^a   Shergill, Sukhwinder S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; PLACEBO;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SENSITIZATION; ELECTROENCEPHALOGRAM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUSIFORM GYRUS; HUMAN; MALE; MENTAL PERFORMANCE; MIDDLE FRONTAL GYRUS; PRECUNEUS; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCHIZOPHRENIA; SUPERIOR FRONTAL GYRUS; TEMPORAL GYRUS; TREATMENT RESPONSE; UNITED KINGDOM; WORKING MEMORY;

ADULT; AMPHETAMINE; BRAIN; CAUDATE NUCLEUS; COGNITION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TEMPORAL LOBE; THALAMUS; TREATMENT OUTCOME;

EID: 79958066244     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.3     Document Type: Article

References (112)

1. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis: preliminary observations. Biol Psychiatry. 1970;2(2):95-107.
2. Connell PH. Amphetamine Psychosis. Glasgow, Scotland: Chapman Hall for the Institute of Psychiatry; 1958.
3. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196-204. (Pubitemid 39208220)
4. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987;91(4):415-433. (Pubitemid 17038204)
5. Lieberman JA, Kane JM, Gadaletta D, Ramos-Lorenzi J, Bergmann K, Wegner J, Novacenko H. Methylphenidate challenge tests and course of schizophrenia. Psychopharmacol Bull. 1985;21(1):123-129. (Pubitemid 15010891)
6. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997;17(4):205-229. (Pubitemid 27440642)
7. Segal DS, Kuczenski R. Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. J Pharmacol Exp Ther. 1997;282(2):561-573. (Pubitemid 27340153)
8. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997;94(6):2569-2574. (Pubitemid 27136916)
9. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46(1):56-72. (Pubitemid 29296818)
10. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996;93(17):9235-9240.
11. Kalivas PW, Richardson-Carlson R, Van Orden G. Cross-sensitization between foot shock stress and enkephalin-induced motor activity. Biol Psychiatry. 1986;21(10):939-950. (Pubitemid 16037300)
12. Piazza PV, Deminiere JM, le Moal M, Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res. 1990;514(1):22-26. (Pubitemid 20147583)
13. Kalivas PW, Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 1990;5(1):48-58. (Pubitemid 20110621)
14. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine, I: dopamine axon terminals. J Neurosci. 1993;13(1):266-275. (Pubitemid 23028742)
15. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine, II: dopamine perikarya. J Neurosci. 1993;13(1):276-284. (Pubitemid 23028743)
16. Kalivas PW, Sorg BA, Hooks MS. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol. 1993;4(4):315-334. (Pubitemid 23258355)
17. Mueller K. Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine. Pharmacol Biochem Behav. 1993;45(1):71-76.
18. Paulson PE, Robinson TE. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse. 1995;19(1):56-65.
19. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986;396(2):157-198. (Pubitemid 16100809)
20. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16(3):223-244.
21. Gur RC, Gur RE. Hypofrontality in schizophrenia: RIP. Lancet. 1995;345(8962):1383-1384.
22. Manoach DS. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res. 2003;60(2-3):285-298. (Pubitemid 36184716)
23. Weinberger DR, Berman KF. Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci. 1996;351(1346):1495- 1503. (Pubitemid 27005376)
24. Tenn CC, Fletcher PJ, Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res. 2003;64(2-3):103-114. (Pubitemid 37412332)
25. Tenn CC, Kapur S, Fletcher PJ. Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berl). 2005;180(2):366-376. (Pubitemid 40909683)
26. Featherstone RE, Rizos Z, Kapur S, Fletcher PJ. A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or longterm memory. Behav Brain Res. 2008;189(1):170-179.
27. Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl). 2005;183(2):190-200. (Pubitemid 41609271)
28. Shoblock JR, Maisonneuve IM, Glick SD. Differences between d-methamphetamine and d-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology (Berl). 2003;170(2):150-156. (Pubitemid 37421526)
29. Stefani MR, Moghaddam B. Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res. 2002;134(1-2):267-274. (Pubitemid 34912706)
30. Castner SA, Vosler PS, Goldman-Rakic PS. Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex. Biol Psychiatry. 2005;57(7):743-751. (Pubitemid 40487918)
31. Castner SA, al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB, Goldman-Rakic PS. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine. Neuropsychopharmacology. 2000;22(1):4-13.
32. Castner SA, Goldman-Rakic PS. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology. 1999;20(1):10-28. (Pubitemid 29010336)
33. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl). 1994;116(2):143-151. (Pubitemid 24317040)
34. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251(4996):947-950. (Pubitemid 21926192)
35. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995;376(6541):572-575.
36. Durstewitz D, Seamans JK, Sejnowski TJ. Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J Neurophysiol. 2000;83(3):1733-1750. (Pubitemid 30159594)
37. Seamans JK, Durstewitz D, Christie BR, Stevens CF, Sejnowski TJ. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A. 2001;98(1):301-306. (Pubitemid 32095904)
38. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci. 2002;22(9):3708-3719. (Pubitemid 37465776)
39. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474-1486.
40. Finlay JM, Zigmond MJ, Abercrombie ED. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience. 1995;64(3):619-628.
41. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003;100(10):6186-6191. (Pubitemid 36576952)
42. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, Saper CB, Rauch SL. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry. 2000;48(2):99-109. (Pubitemid 30618799)
43. Manoach DS, Press DZ, Thangaraj V, Searl MM, Goff DC, Halpern E, Saper CB, Warach S. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry. 1999;45(9):1128-1137. (Pubitemid 29236553)
44. Copolov DL, Seal ML, Maruff P, Ulusoy R, Wong MT, Tochon-Danguy HJ, Egan GF. Cortical activation associated with the experience of auditory hallucinations and perception of human speech in schizophrenia: a PET correlation study. Psychiatry Res. 2003;122(3):139-152. (Pubitemid 36412190)
45. Shergill SS, Brammer MJ, Williams SC, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry. 2000;57(11):1033-1038.
46. Krystal JH, Anand A, Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry. 2002;59(7):663-664. (Pubitemid 34747249)
47. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214.
48. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997;16(5):357-372. (Pubitemid 27211734)
49. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res. 1998;83(3):149-162. (Pubitemid 28522506)
50. Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC. Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain. 2007;130(pt 9):2387-2400. (Pubitemid 47327635)
51. Castner SA, Goldman-Rakic PS. Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates. Biol Psychiatry. 2003;54(2):105-110. (Pubitemid 36859769)
52. Castner SA, Williams GV. From vice to virtue: insights from sensitization in the nonhuman primate. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(8):1572-1592. (Pubitemid 47625704)
53. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci. 1995;3(2):89-97.
54. Frith CD, Friston KJ, Herold S, Silbersweig D, Fletcher P, Cahill C, Dolan RJ, Frackowiak RS, Liddle PF. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br J Psychiatry. 1995;167(3):343-349. (Pubitemid 26197748)
55. Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry. 2002;51(12):1008-1011. (Pubitemid 34607719)
56. Shergill SS, Brammer MJ, Fukuda R, Williams SC, Murray RM, McGuire PK. Engagement of brain areas implicated in processing inner speech in people with auditory hallucinations. Br J Psychiatry. 2003;182:525-531. (Pubitemid 36649199)
57. Shergill SS, Kanaan RA, Chitnis XA, O'Daly O, Jones DK, Frangou S, Williams SC, Howard RJ, Barker GJ, Murray RM, McGuire P. A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry. 2007;164(3):467-473. (Pubitemid 46513161)
58. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23. (Pubitemid 36042420)
59. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature. 1995;378(6553):180-182.
60. Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci. 1996;16(21):7055-7062. (Pubitemid 26359384)
61. Friston KJ. The disconnection hypothesis. Schizophr Res. 1998;30(2):115-125. (Pubitemid 28156976)
62. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry. 2006;59(10):929-939. (Pubitemid 44288017)
63. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull. 2009; 35(3):509-527.
64. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry. 2006;63(12):1386-1395. (Pubitemid 44878522)
65. Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry. 2005;62(3):254-262. (Pubitemid 40990970)
66. Gevins A, Cutillo B. Spatiotemporal dynamics of component processes in human working memory. Electroencephalogr Clin Neurophysiol. 1993;87(3):128-143. (Pubitemid 23272868)
67. Haertzen CA, Hill HE. Assessing subjective effects of drugs: an index of carelessness and confusion for use with the Addiction Research Center Inventory (ARCI). J Clin Psychol. 1963;19:407-412.
68. Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia. 1963;4:155-166.
69. Haertzen CA, Hickey JE. Addiction Research Center Inventory (ARCI): measurement of euphoria and other drug effects. In: Bozarth MA, ed. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York, NY: Springer-Verlag; 1987:489-524.
70. McNair DM, Lorr M, Droppleman LF. EdITS Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service; 1992.
71. Kumari V, Mulligan OF, Cotter PA, Poon L, Toone BK, Checkley SA, Gray JA. Effects of single oral administrations of haloperidol and d-amphetamine on prepulse inhibition of the acoustic startle reflex in healthy male volunteers. Behav Pharmacol. 1998;9(7):567-576. (Pubitemid 28552550)
72. Strakowski SM, Sax KW. Progressive behavioral response to repeated damphetamine challenge: further evidence for sensitization in humans. Biol Psychiatry. 1998;44(11):1171-1177. (Pubitemid 28547152)
73. Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM. Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology. 2001;25(4):548-554. (Pubitemid 32830959)
74. Strakowski SM, Sax KW, Setters MJ, Keck PE Jr. Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans. Biol Psychiatry. 1996;40(9):872-880. (Pubitemid 26356721)
75. Andersson JL, Hutton C, Ashburner J, Turner R, Friston K. Modeling geometric deformations in EPI time series. Neuroimage. 2001;13(5):903-919. (Pubitemid 32848335)
76. Hutton C, Bork A, Josephs O, Deichmann R, Ashburner J, Turner R. Image distortion correction in fMRI: a quantitative evaluation. Neuroimage. 2002;16(1):217-240. (Pubitemid 34852485)
77. Friston KJ, Frith CD, Turner R, Frackowiak RS. Characterizing evoked hemodynamics with fMRI. Neuroimage. 1995;2(2):157-165.
78. Friston KJ, Holmes AP, Poline JB, Grasby PJ, Williams SC, Frackowiak RS, Turner R. Analysis of fMRI time-series revisited. Neuroimage. 1995;2(1):45-53.
79. Friston KJ, Fletcher P, Josephs O, Holmes A, Rugg MD, Turner R. Event-related fMRI: characterizing differential responses. Neuroimage. 1998;7(1):30-40. (Pubitemid 28355037)
80. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography, I: accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034-1057. (Pubitemid 32823740)
81. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273-289. (Pubitemid 34852226)
82. Wright IC, McGuire PK, Poline JB, Travere JM, Murray RM, Frith CD, Frackowiak RS, Friston KJ. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. Neuroimage. 1995;2(4):244-252. (Pubitemid 26018339)
83. Strafella AP, Ko JH, Grant J, Fraraccio M, Monchi O. Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET study. Eur J Neurosci. 2005;22(11):2946-2952. (Pubitemid 41811290)
84. Fu CH, McIntosh AR, Kim J, Chau W, Bullmore ET, Williams SC, Honey GD, McGuire PK. Modulation of effective connectivity by cognitive demand in phonological verbal fluency. Neuroimage. 2006;30(1):266-271. (Pubitemid 43243217)
85. Breakspear M, Terry JR, Friston KJ. Modulation of excitatory synaptic coupling facilitates synchronization and complex dynamics in a biophysical model of neuronal dynamics. Network. 2003;14(4):703-732. (Pubitemid 37550269)
86. Fletcher PC, McKenna PJ, Frith CD, Grasby PM, Friston KJ, Dolan RJ. Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging. Arch Gen Psychiatry. 1998;55(11):1001-1008. (Pubitemid 28506842)
87. Spence SA, Liddle PF, Stefan MD, Hellewell JS, Sharma T, Friston KJ, Hirsch SR, Frith CD, Murray RM, Deakin JF, Grasby PM. Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk: focal dysfunction and distributed disconnectivity reappraised. Br J Psychiatry. 2000;176:52-60. (Pubitemid 30051089)
88. Crossley NA, Mechelli A, Fusar-Poli P, Broome MR, Matthiasson P, Johns LC, Bramon E, Valmaggia L, Williams SC, McGuire PK. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp. 2009;30(12):4129-4137.
89. Fu CH, Suckling J, Williams SC, Andrew CM, Vythelingum GN, McGuire PK. Effects of psychotic state and task demand on prefrontal function in schizophrenia: an fMRI study of overt verbal fluency. Am J Psychiatry. 2005;162(3):485-494. (Pubitemid 40343915)
90. Williams GV, Castner SA. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience. 2006;139(1):263-276.
91. Williams SM, Goldman-Rakic PS. Characterization of the dopaminergic innervation of the primate frontal cortex using a dopamine-specific antibody. Cereb Cortex. 1993;3(3):199-222. (Pubitemid 23184929)
92. Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex. 1998;8(4):321-345. (Pubitemid 28280738)
93. Garris PA, Collins LB, Jones SR, Wightman RM. Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J Neurochem. 1993;61(2):637-647. (Pubitemid 23215809)
94. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990;13(7):266-271. (Pubitemid 20193456)
95. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381. (Pubitemid 16055790)
96. Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, Moore H, Kandel ER. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006;49(4):603-615. (Pubitemid 43221894)
97. Monchi O, Petrides M, Mejia-Constain B, Strafella AP. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain. 2007;130(pt 1):233-244. (Pubitemid 46026238)
98. Monchi O, Taylor JG, Dagher A. A neural model of working memory processes in normal subjects, Parkinson's disease and schizophrenia for fMRI design and predictions. Neural Netw. 2000;13(8-9):953-973.
99. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci. 2004;19(3):755-760. (Pubitemid 38241314)
100. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67(3):231-239.
101. Knutson B, Bjork JM, Fong GW, Hommer D, Mattay VS, Weinberger DR. Amphetamine modulates human incentive processing. Neuron. 2004;43(2):261-269. (Pubitemid 38942965)
102. Jackson ME, Frost AS, Moghaddam B. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens. J Neurochem. 2001;78(4):920-923. (Pubitemid 32777992)
103. Sesack SR, Carr DB. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav. 2002;77(4-5):513-517. (Pubitemid 36084394)
104. Cador M, Bjijou Y, Cailhol S, Stinus L. D-amphetamine-induced behavioral sensitization: implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation. Neuroscience. 1999;94(3):705-721. (Pubitemid 29474959)
105. Bonci A, Malenka RC. Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci. 1999;19(10):3723-3730. (Pubitemid 29222248)
106. Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000;27(2):349-357.
107. Cepeda C, Levine MS. Where do you think you are going? the NMDA-D1 receptor trap. Sci STKE. 2006;2006(333):pe20.
108. Bower EA, Phelan JR. Use of amphetamines in the military environment. Lancet. 2003;362(suppl):s18-s19.
109. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702-705.
110. Booij L, Welfeld K, Leyton M, et al. Cross-sensitization between stimulants and stress in humans: behavioral and neurochemical correlates. In: 50th Annual Conference of Scandinavian College of Neuropsychopharmacology (SCNP). Vol 2. Copenhagen, Denmark: Scandinavian College of Neuropsychopharmacology (SCNP); 2009.
111. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry. 2008; 165(5):553-555. (Pubitemid 351705328)
112. Boileau I, Dagher A, Leyton M, Welfeld K, Booij L, Diksic M, Benkelfat C. Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine. J Neurosci. 2007;27(15):3998-4003. (Pubitemid 46597158)